성윤경 교수

In the overall analysis, etoricoxib, celecoxib, and aceclofenac had the highest rankings for improving WOMAC pain. The ability to improve knee OA symptoms may differ depending on baseline pain and radiologic features.

This guideline is intended to guide clinicians in the prevention and treatment of GIOP.

BACKGROUND: To identify knee osteoarthritis (OA) patients among OA patients in the claims database. METHODS: All patients with OA diagnostic codes for any sites (M15 to M19) in 2014 were recruited from a single academic referral hospital. After excluding patients who had inflammatory arthritis or were less than 50 years of age, we identified data for the overall OA population. Radiographic knee OA of Kellgren and Lawrence grades ≥2 is considered the gold standard for knee OA, and we evaluated th

TBS showed better correlation with MOF-FRAX score than BMD, and it was superior to BMD in identifying prevalent VFs in RA patients, especially who are in use of GCs.

BACKGROUND: Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed to estimate the incidence of malignancy in early RA patients and to evaluate the relative risk of malignancy with use of bDMARDs. METHODS: A retrospective cohort of incident RA patients was establish

OBJECTIVE: To determine the prevalence of systemic damage in Korean patients with systemic lupus erythematosus (SLE) and to elucidate associations between possible risk factors and the presence of damage. METHODS: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was used to quantify systemic damage in 588 patients who were enrolled consecutively at the Hospital for Rheumatic Diseases, Seoul, South Korea. The frequencies and means of each

OBJECTIVES: To evaluate the risks of overall and site-specific malignancies in Korean patients with primary Sjögren's syndrome (pSS). METHODS: Using the Korean nationwide healthcare claims database, we constructed a retrospective cohort for prevalent pSS aged over 50 years. After enrollment between January 2012 and December 2014, patients were followed until the development of any malignancy, or until December 2015. Crude incidence rates of malignancies of pSS patients were calculated, and their